<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04539223</url>
  </required_header>
  <id_info>
    <org_study_id>SLICE-CEA-001</org_study_id>
    <nct_id>NCT04539223</nct_id>
  </id_info>
  <brief_title>A Study of Evolocumab on Carotid Artery Atherosclerotic Plaque Morphology Prior to Carotid EndArterectomy</brief_title>
  <acronym>SLICE-CEA</acronym>
  <official_title>Study of Lipids Inside the Carotid With Evolocumab: A Randomized Trial of Evolocumab on Carotid Artery Atherosclerotic Plaque Morphology Prior to Carotid EndArterectomy (SLICE-CEA CardioLink-8 Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canadian Medical and Surgical Knowledge Translation Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Medical and Surgical Knowledge Translation Research Group</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, open label study with blinded outcome assessment to&#xD;
      evaluate the impact of additional/intensive LDL-cholesterol reduction with evolocumab on&#xD;
      carotid artery atherosclerotic plaques in higher risk subjects with severe asymptomatic but&#xD;
      vulnerable plaques.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Twenty-six week treatment with or without evolocumab in addition to current medical management.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in lipid rich necrotic core (LRNC) volume</measure>
    <time_frame>Baseline to end of treatment (average of 6 months)</time_frame>
    <description>As measured by MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in vessel wall volume</measure>
    <time_frame>Baseline to end of treatment (average of 6 months)</time_frame>
    <description>As measured by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in vessel lumen volume</measure>
    <time_frame>Baseline to end of treatment (average of 6 months)</time_frame>
    <description>As measured by MRI</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Plaque Histology and Morphology</measure>
    <time_frame>At the end of treatment (average of 6 months)</time_frame>
    <description>Obtained at time of CEA</description>
  </other_outcome>
  <other_outcome>
    <measure>Lipid Levels</measure>
    <time_frame>Baseline to end of treatment (average of 6 months)</time_frame>
    <description>Serum lipid levels</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Carotid Artery Stenosis</condition>
  <condition>Asymptomatic Carotid Artery Stenosis</condition>
  <arm_group>
    <arm_group_label>Drug (Evolocumab)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individuals randomized to this arm will administer Evolocumab subcutaneously (SC) every two weeks (Q2W) for 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Drug (Standard of Care)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Individuals randomized to this arm will not administer a placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evolocumab</intervention_name>
    <description>Autoinjector 1-mL deliverable volume of 140 mg/mL</description>
    <arm_group_label>Drug (Evolocumab)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¥ 40 years old&#xD;
&#xD;
          2. Significant (70-99%) carotid artery stenosis on one side, as measured by duplex&#xD;
             ultrasound or angiogram&#xD;
&#xD;
          3. Asymptomatic carotid stenosis (no history of ipsilateral stroke or TIA within 180&#xD;
             days)&#xD;
&#xD;
          4. Deemed to be fit for carotid endarterectomy&#xD;
&#xD;
          5. At least one of the following high risk features: (a) prior stroke &gt;6months prior to&#xD;
             randomization; (b) peripheral artery disease; (c) current smoker; and/or (d) type II&#xD;
             diabetes&#xD;
&#xD;
          6. On a moderate to high intensity statin therapy (defined as atorvastatin 40-80mg daily,&#xD;
             rosuvastatin 20-40mg or simvastatin 40mg daily) unless a lower dose, or another statin&#xD;
             or non-statin therapy is clinically justified&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindications for MRI (pacemaker; neurostimulator; non-removable metal fragments&#xD;
             in the eye; etc.)&#xD;
&#xD;
          2. Patients in whom additional lowering of LDL-C with evolocumab is deemed to be&#xD;
             clinically inappropriate&#xD;
&#xD;
          3. Currently taking simvastatin &gt;40mg/day&#xD;
&#xD;
          4. High risk comorbidities such as severe heart failure, severe COPD, severe renal&#xD;
             disease, known severe hepatic impairment, unstable coronary syndrome, and/or advanced&#xD;
             dementia&#xD;
&#xD;
          5. eGFR &lt;30 mL/min/1.73m2&#xD;
&#xD;
          6. Current, prior within past year, or known planned use of PCSK9 inhibition treatment&#xD;
&#xD;
          7. Known intolerance or allergy to evolocumab or other PCSK9 inhibitors&#xD;
&#xD;
          8. Known latex allergy&#xD;
&#xD;
          9. Women who are pregnant or breastfeeding&#xD;
&#xD;
         10. Women of child bearing potential who are unwilling to use proper family planning or&#xD;
             birth control methods to avoid pregnancy. Women are considered post-menopausal and not&#xD;
             of childbearing potential after 12 months of natural (spontaneous) amenorrhea or have&#xD;
             had a surgical procedure such as hysterectomy which makes pregnancy impossible&#xD;
&#xD;
         11. Inability to comply with protocol-required study visits or procedures, including&#xD;
             administration of study drug&#xD;
&#xD;
         12. Severe concomitant disease that is expected to reduce life expectancy to less than 5&#xD;
             years&#xD;
&#xD;
         13. Participation in another investigational device or drug study which is likely to&#xD;
             affect the primary outcome, within 30 days of planned initiation of study drug&#xD;
&#xD;
        If all eligibility criteria listed above are met, the participant will undergo a&#xD;
        time-of-flight MR angiogram, where one additional inclusion criteria will be assessed to&#xD;
        confirm eligibility:&#xD;
&#xD;
        1. Evidence of IPH on MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammed Al-Omran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unity Health Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shira Brodutch</last_name>
    <phone>226-606-6610</phone>
    <email>Shira.Brodutch@unityhealth.to</email>
  </overall_contact>
  <location>
    <facility>
      <name>North York Diagnostic and Cardiac Centre</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <zip>M6B 3H7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Al-Omran</last_name>
      <email>Mohammed.Al-Omran@unityhealth.to</email>
    </contact>
    <investigator>
      <last_name>Mohammed Al-Omran</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjay Yagnik</last_name>
      <phone>416 864 6060</phone>
      <phone_ext>2920</phone_ext>
      <email>Sanjay.Yagnik@unityhealth.to</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 30, 2020</study_first_submitted>
  <study_first_submitted_qc>September 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2020</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CEA</keyword>
  <keyword>Carotid EndArterectomy</keyword>
  <keyword>Evolocumab</keyword>
  <keyword>Carotid Artery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carotid Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Plaque, Atherosclerotic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Evolocumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

